1. Home
  2. BCG vs GBIO Comparison

BCG vs GBIO Comparison

Compare BCG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.99

Market Cap

29.6M

Sector

N/A

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.30

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
GBIO
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.6M
35.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BCG
GBIO
Price
$1.99
$5.30
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$10.67
AVG Volume (30 Days)
2.0M
40.1K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$178,203,000.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$57.50
N/A
Revenue Growth
10.19
N/A
52 Week Low
$1.36
$3.00
52 Week High
$6.00
$13.00

Technical Indicators

Market Signals
Indicator
BCG
GBIO
Relative Strength Index (RSI) 46.39 50.63
Support Level $2.33 $5.22
Resistance Level $3.07 $5.64
Average True Range (ATR) 0.33 0.24
MACD -0.06 0.05
Stochastic Oscillator 8.32 59.32

Price Performance

Historical Comparison
BCG
GBIO

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: